Tangramed Biotech is a French biotechnology company developing a new way to design therapies for complex diseases.

Many severe diseases, including neurodegenerative diseases and cancer, are driven by multiple biological mechanisms that vary across patients, tissues and disease stages. This complexity is one reason why single-target therapies often fail to deliver robust clinical benefit.

Tangramed addresses this challenge through Integral Therapy Design (ITD), a development framework for designing and benchmarking rational multimodal therapies (MMTs). The approach combines PleoBot™, Tangramed’s proprietary AI-assisted network-pharmacology platform, with Patient Avatar Cohort (PAC), a patient-derived robustness-testing capability designed to assess therapeutic concepts across biological diversity.

Tangramed supports biopharma partners with target and pathway prioritization, asset positioning, target-combination discovery, Multimodal Therapy design, and scientific or investment diligence. Selected concepts may progress into partner-funded ITD programs using both PleoBot™ and PAC.

The company’s first flagship ITD application is focused on Amyotrophic Lateral Sclerosis (ALS), a fatal and highly heterogeneous neurodegenerative disease with major unmet medical need.

From complex disease biology to actionable therapeutic decisions.

www.tangramed.com
BD@tangramed.com

Tangramed Biotech

Org chart

Teams

Offices

Tangramed Biotech

Org chart

Teams

Offices

Related companies